Patients With Melanoma Treated With Immune Checkpoint Inhibitors

Comparing Melanoma Immunotherapy Outcomes in Key Clinical Trials

During a live event, Ahmad Tarhini, MD, PhD, discussed key melanoma trials with varying survival and toxicity profiles.

High-Grade Toxicity Rates Influence Choice of IO in Melanoma

During a live event, James W. Smithy, MD, MHS, and other oncologists discussed the tolerability of different immune checkpoint inhibitor regimens in melanoma including alternate dosing strategies.

Experience Managing irAEs Vital for Both Oncologists and Specialists

During a live event, James W. Smithy, MD, MHS, and other oncologists discussed how their experience with immune-related adverse events in metastatic melanoma has developed over time.

Post–PD-1 Data in Melanoma Offers Insight into IO Approaches

During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed goals and barriers to treatment when using combination immunotherapy for metastatic melanoma in the second article of a 2-part series.

Response Time and BRAF Status Factor Into IO Selection for Melanoma

During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed how data from the CheckMate-067 and RELATIVITY-047 affect their choice of therapy for metastatic melanoma in the first article of a 2-part series.

Considering the Changing Treatment Landscape for Patients With Melanoma

Evan Lipson, MD, discusses the evolving treatment landscape for advanced melanoma.

Oncologists Experience Improved Survival in Patients With Melanoma

Evan Lipson, MD, discusses feedback he’s received from colleagues about responses in patients with melanoma.

RELATIVITY-047 vs CheckMate 067 Matched Cohorts in Melanoma Show Similar Efficacy

During a Case-Based Roundtable® event, Ahmad Tarhini, MD, PhD, discussed the indirect comparison of ipilimumab plus nivolumab and nivolumab/relatlimab in advanced melanoma in the second article of a 2-part series.

Relatlimab/Nivolumab in Melanoma Improves Brain Metastasis–Free Survival

During a Case-Based Roundtable® event, Ahmad Tarhini, MD, PhD, discussed the 2024 update to the RELATIVITY-047 trial in advanced melanoma in the first article of a 2-part series.

Tawbi Discusses the Role of Brain Metastases and PD-L1 Status in Melanoma

During a Case-Based Roundtable® event, Hussein A. Tawbi, MD, PhD, and participants look at benefits of nivolumab combinations for brain metastases and PD-L1 positivity in the metastatic melanoma population in the second article of a 2-part series.

Nivolumab Combinations Debated for a Patient With Metastatic Melanoma

During a Case-Based Roundtable® event, Hussein A. Tawbi, MD, PhD, and participants considered nivolumab/ipilimumab and nivolumab/relatlimab as options for a patient with metastatic melanoma in the first article of a 2-part series.

Similar Efficacy in Melanoma Shown in Indirect Comparison of PD-1/LAG3 vs PD-1/CTLA-4

During a Case-Based Roundtable® event, Michael A. Postow, MD, discussed an indirect treatment comparison of nivolumab plus relatlimab vs nivolumab plus ipilimumab in patients with advanced melanoma in the second article of a 2-part series.

Interpreting Nivolumab/Relatlimab PFS/ORR Benefit, Safety in Melanoma

During a Case-Based Roundtable® event, Michael A. Postow, MD, reviewed the use of nivolumab plus relatlimab for patients with advanced melanoma in the first article of a 2-part series.

Patient Preference Plays Limited Role in Selection of Therapy for Melanoma

During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants whether factors such as patient preference influence their choice of melanoma treatment in the second article of a 2-part series.

Management of Immune-Related Toxicities in Melanoma Has Improved Over Time

During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants how their experience with immunotherapy toxicities has changed over time in the first article of a 2-part series.

Dosing and Regimen Changes Promote Tolerability in Advanced Melanoma

During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed dosing considerations and toxicity when choosing combination treatment for patients with melanoma. This is the second of 2 articles based on this event.

Experience Shapes Use of Dual Immunotherapy in Advanced Melanoma

During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed what patient factors and other considerations affect the choice of immunotherapy for patients with advanced BRAF-negative melanoma. This is the first of 2 articles based on this event.

Clinical Experiences With Nivolumab/Relatlimab for Metastatic Melanoma

During a Targeted Oncology™ Case-Based Roundtable™ event, Hussein A. Tawbi, MD, PhD, asked several participants to share their experiences treating patients with metastatic melanoma with nivolumab plus relatlimab. This is the second of 2 articles based on this event.

Discussing Rationale for Combination Therapy in Metastatic Melanoma

During a Targeted Oncology™ Case-Based Roundtable™ event, Hussein A. Tawbi, MD, PhD, and participants discussed which first-line therapy they would recommend for a 78-year-old patient with metastatic melanoma and no BRAF-activating mutation. This is the first of 2 articles based on this event.

Role of Tolerability in Using Immunotherapy for Metastatic Melanoma

During a Targeted Oncology™ Case-Based Roundtable™ event, April K.S. Salama, MD, and other physicians discussed which patients are more challenging when it comes to tolerating dual immunotherapy as frontline therapy for metastatic melanoma. This is the second of 2 articles based on this event.

Immunotherapy Options for an Older Patient With Metastatic Melanoma

During a Targeted Oncology™ Case-Based Roundtable™ event, April K.S. Salama, MD, discussed treatment approaches for a 78-year-old patient with metastatic melanoma discovered 12 years after surgical resection.

Physicians Discuss Frontline Immunotherapies for Metastatic Melanoma

During a Targeted Oncology™ Case-Based Roundtable™ event, Evan J. Lipson, MD, and participants discussed factors influencing their choice of immunotherapy for a patient with BRAF-negative metastatic melanoma.

Nivolumab/Relatlimab Shows PFS/OS Benefit Over Nivolumab in Melanoma

During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed data from the RELATIVITY-047 trial of nivolumab plus relatlimab for patients with metastatic melanoma. This is the second of 2 articles based on this event.

Efficacy and Tolerability of Immunotherapies Discussed for Melanoma

During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed with other oncologists what efficacy and safety data aid them in choosing an immunotherapy regimen for patients with metastatic melanoma. This is the first of 2 articles based on this event.

The Significance of Nivolumab Plus Relatlimab for Advanced Melanoma

Jason Luke, MD, discussed the role played by the combination of nivolumab plus relatlimab in patients with advanced melanoma.